10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Latest (Page 8)
SOLAR Trial: Revolutionizing Rectal Cancer Treatment with Short-Course Radiotherapy
New trial compares short-course radiotherapy plus chemotherapy to standard chemoradiotherapy for rectal cancer
SYNERGY Trial: Oleclumab Falls Short in Boosting TNBC Chemo-Immunotherapy
Phase I/II trial shows adding oleclumab to standard therapy doesn't improve outcomes in advanced TNBC.
ATRA Boosts FOLFOX4 Efficacy in Advanced Liver Cancer with Metastasis
Study shows FOLFOX4 + ATRA improves survival in advanced hepatocellular carcinoma with metastasis
New Hope for Acute Myeloid Leukemia: Cusatuzumab Shows Promise in Clinical Trial
Cusatuzumab plus azacitidine shows efficacy in treating newly diagnosed acute myeloid leukemia
Decitabine vs. Standard Chemo: A New Approach for Older AML Patients
Study compares 10-day decitabine to standard chemo for older AML patients eligible for transplant
Breakthrough Treatment Combo Shows Promise for HER2+ Metastatic Breast Cancer
Novel drug combination significantly improves progression-free survival in HER2+ metastatic breast cancer
New Drug Combo Falls Short in Ovarian Cancer Trial
Phase III trial of ofranergene obadenovec plus paclitaxel fails to improve outcomes in ovarian cancer
Fosfomycin vs Ciprofloxacin: A New Approach to Prevent Infections in High-Risk Blood Cancer Patients
Study compares fosfomycin to ciprofloxacin for preventing infections in leukemia and transplant patients
Pembrolizumab Plus Chemo Boosts Survival in Advanced Gastric Cancer
Study shows pembrolizumab with chemotherapy improves outcomes in HER2-negative gastric cancer
Amivantamab Plus Chemotherapy: A New Frontline Treatment for NSCLC with EGFR Exon 20 Insertions
Study shows amivantamab-chemotherapy combo significantly improves outcomes in NSCLC with EGFR mutations
Durvalumab Boosts Survival in Early-Stage Lung Cancer
Study finds perioperative durvalumab plus chemotherapy improves outcomes in resectable NSCLC
Selpercatinib Outperforms Standard Treatment for Advanced Thyroid Cancer
Targeted RET inhibitor selpercatinib shows superior efficacy and safety in advanced thyroid cancer trial